AzTrials
AzTrials

Cerebral Palsy (CP)NCT07539389

Safety and Effectiveness of Bambini Kids Robot-Assisted Gait Training (RAGT) in Children With Cerebral Palsy

A study testing Exoskeleton and Rehabilitation physical therapy in people with Cerebral Palsy (CP), run by COSMO ROBOTICS CO., Ltd at 1 site in South Korea.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Cerebral palsy (CP) is a common cause of gait impairment in children, leading to limitations in mobility and daily activities. Although conventional physical therapy is widely used, it has limitations in delivering consistent and intensive training. Read more about this study

Who is it for?
Ages 2 to 10 years
Conditions the study is for
Cerebral Palsy (CP)
What is being tested?
Exoskeleton and Rehabilitation physical therapy
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteSouth Korea
Study dates
13 Apr 2026to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 10 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Subjects eligible for participation in this clinical investigation shall meet all of the following criteria.
  • Patient diagnosed with Cerebral Palsy
  • Age from 2 to 10 years old
  • Classified as Levels II to IV according to GMFCS
  • Manual Muscle Testing, MMT score of 0 to 4
  • Modified Ashworth Scale, MAS score of 3 and under
Show all 9Show fewer
  • Subjects with sufficient cognitive function to comply with study procedures
  • Subjects with adequate upper limb function required for device use and study procedures
  • Subjects who meet the physical requirements for use of the medical device as defined by the manufacturer

Who cannot join

  • Subjects meeting any of the following criteria are not eligible for participation in the clinical investigation.
  • Subjects who do not meet the criteria of age, height, weight, body dimensions, or joint range of motion
  • Subjects with skin lesions, pressure sores, infections, or other conditions at area where device touches and makes difficult to use device
  • Classified as Levels V according to GMFCS
  • Subjects with severe spasticity (MAS > 3), or those at risk of significant worsening of spasticity after training.
  • Subjects unable to maintain an upright standing position for at least 15 minutes (e.g., due to autonomic dysreflexia or orthostatic hypotension)
Show all 12Show fewer
  • Subjects with significant cardiovascular disease or a history of myocardial infarction within the past 6 months
  • Subjects with medical conditions that are contraindications for use of the medical device as defined by the manufacturer.
  • Subjects for whom weight-bearing, standing, or gait training is medically contraindicated (e.g., fractures, severe osteoporosis, severe joint deformity, or joint instability)
  • Subjects who have received treatments affecting muscle tone within the past 4 months, such as botulinum toxin injections or baclofen pump implantation
  • Subjects who experience adverse events or undesirable side effects during the clinical investigation that make continued participation difficult
  • Subjects whom the investigator judges to be unsuitable for participation or continuation in the clinical investigation.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Seung Hak Lee, Associate Professor contact

82 + 02) 3010-3795

seunghak@gmail.com

South Korea1 site, 1 recruiting
  • Asan Medical center

    Songpa, Seoul, 05505

    Associate Professor, 82 + 02) 3010-3795, seunghak@gmail.com

    Recruiting

Other trials in South Korea

About this study

Official title: Safety and Effectiveness of Bambini Kids Robot-Assisted Gait Training in Children With Cerebral Palsy: A Randomized Clinical Trial

Cerebral palsy (CP) is a common cause of gait impairment in children, leading to limitations in mobility and daily activities. Although conventional physical therapy is widely used, it has limitations in delivering consistent and intensive training. Robot-assisted gait training (RAGT) has emerged as a promising approach to provide repetitive, high-intensity, and task-specific training, with potential benefits in gait function and motor performance.

The Bambini Kids exoskeleton is a pediatric robotic device designed to assist lower-limb movements, including hip, knee, and ankle joints, to facilitate more natural gait patterns.

This study aims to evaluate the safety and clinical performance of Bambini Kids in children with cerebral palsy and to generate clinical evidence to support its use in real-world rehabilitation settings.

Read the detailed description

Cerebral palsy (CP) is one of the most common causes of gait impairment in children, and it's a non-progressive neurodevelopmental disorder that results in permanent impairments in motor function and postural control. The prevalence of cerebral palsy in Korea has been reported to be approximately 2.6 per 1,000 individuals. Patients with CP experience limitations in gait and activities of daily living due to muscle spasticity, muscle weakness, and impairments in balance and coordination, which consequently lead to reduced independence and decreased quality of life.

Physical activity is essential for promoting overall health in children with cerebral palsy, and has been shown to improve stability, balance, overall motor function, and aerobic capacity, while reducing the risk of depression and enhancing key functional domains such as social participation and quality of life. To achieve these benefits, conventional physical therapy approaches, including partial body weight-supported gait training, task-oriented training, and treadmill-based training, have been widely used; however, these approaches are associated with substantial physical burden on therapists and limitations in consistently providing repetitive and high-intensity training.

To address these limitations, robot-assisted gait training (RAGT) is getting attention in the field of rehabilitation. RAGT enables the consistent delivery of high-intensity and high-frequency repetitive training in accordance with physiological gait patterns and allows automatic recording of training parameters for objective analysis and comparison. In addition, some wearable exoskeleton can be applied in non-clinical settings, thereby expanding their potential use beyond hospital environments.

The therapeutic effects of robot-assisted gait training (RAGT) have been demonstrated in adult patients with spinal cord injury (SCI) and stroke through multiple randomized controlled trials and systematic reviews, showing positive impacts on gait ability, muscle strength, balance, and recovery of activities of daily living. Studies in children with cerebral palsy have also reported that RAGT has a beneficial effect on activity-related outcomes such as standing ability, gait speed, and walking distance. Early application of rehabilitation in children during developmental stages is of particular clinical importance, as it may promote neuroplasticity during periods when gait patterns and motor function remain modifiable, thereby potentially preventing long-term progression of disability. In a recent multicenter clinical study, significant improvements in gross motor function, balance control, and gait patterns were observed after 6 weeks of robot-assisted gait training, and these effects were maintained at follow-up. Borggraefe et al. reported that patients with milder impairment (GMFCS Levels I-II) showed significantly greater improvements in Gross Motor Function Measure(GMFM-88) dimensions D and E compared to those with moderate to severe impairment (GMFCS Levels III-IV). However, some studies have suggested that the relatively short duration of interventions may have led to an overestimation of treatment effects, indicating the need for further validation.

Recently, in addition to robot-assisted training in medical institutions, studies have actively investigated the feasibility and effectiveness of using exoskeleton robots in home and community settings for children with cerebral palsy. This approach has gained attention as a novel strategy to improve access to therapy and to support continuous rehabilitation in daily life.

Children with cerebral palsy frequently exhibit limitations in normal movement due to reduced joint range of motion, decreased muscle strength, and abnormal muscle tone. They often present with various gait abnormalities, such as equinus gait and crouch gait. Children with cerebral palsy frequently exhibit limitations in normal movement due to reduced joint range of motion, decreased muscle strength, and abnormal muscle tone. They often present with various gait abnormalities, such as equinus gait and crouch gait. These abnormal gait patterns may lead to secondary deformities over time; therefore, a multidisciplinary approach, in addition to conventional physical therapy, is essential in the rehabilitation of patients with cerebral palsy.

Despite these clinical characteristics, particularly those aged 2-11 years with a height of approximately 100 cm, the evidence on the effectiveness and safety of exoskeleton-based gait training in children with cerebral palsy remains limited. This is also reflected in the current regulatory status both domestically and internationally. Among 22 powered exoskeletons that have received U.S. FDA 510(k) clearance, only one pediatric-specific device-developed by Cyberdyne, Inc. in Japan-has been approved. Similarly, in Korea, only two exoskeletons for pediatric use (Exerciser, orthopaedic, electrically-powered or Robotic-guidance rehabilitation system) have been approved, manufactured by COSMO ROBOTICS CO., Ltd. and ANGEL ROBOTICS Co., Ltd. Among these, Bambini Kids developed by Cosmo Robotics Co., Ltd. is the only device that actively assists not only hip and knee flexion and extension, but also ankle dorsiflexion and plantarflexion, as well as hip abduction and adduction.

To address these clinical limitations, the Bambini Kids exoskeleton has been developed with independent motors at the hip and ankle joints. In addition to the conventional assistance of hip and knee flexion and extension provided by existing exoskeleton systems, the device incorporates four additional motors to actively control ankle dorsiflexion and plantarflexion, as well as hip abduction and adduction. This design enhances joint mobility throughout the gait cycle, ankle propulsion, and pelvic stability. As a result, the device is expected to facilitate the acquisition of more natural and symmetrical gait patterns.

Therefore, this study aims to systematically evaluate the safety and effectiveness of the pediatric exoskeleton Bambini Kids in children with cerebral palsy. Based on the results, it is intended to generate evidence to support regulatory approval and clinical application in overseas markets, and to contribute to the development of strategies for expanding the use of robot-assisted gait training (RAGT) across diverse real-world settings, including home and community environments.

Being tested
Exoskeleton, Rehabilitation physical therapy
Medical subject headings
Cerebral Palsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ExoskeletonDevice

    Also called Bambini Kids

    This device is a powered exoskeleton intended to be worn on lower limbs affected by paralysis or weakness. It is designed to directly actuate the user's lower limb joints via integrated motors to assist or enable gait.

    The subject will have intervention of robot-assisted gait training (RAGT) using Bambini Kids (Cosmo Robotics Co., Ltd) for three sessions per week, 30 minutes per session, for 4 weeks.

  • Rehabilitation physical therapyOther

    The subject will have intervention of one-on-one gait rehabilitation therapy with physical therapist for the same duration as treatment group (three sessions per week, 30 minutes per session, for 4 weeks)

Study groups in NCT07539389
Study groupRoleWhat they receive
Exoskeleton groupExperimentalApply robot-assisted gait training (RAGT) for three sessions per week, a total of 12 sessions.
Receives: Device: Exoskeleton
Conventional Therapy groupActive comparatorApply conventional therapy for three sessions per week, a total of 12 sessions.
Receives: Other: Rehabilitation physical therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gross Motor Function Measure 88 (GMFM-88)

    The Gross Motor Function Measure (GMFM) is a standardized observational assessment tool used to evaluate changes in gross motor function over time in children with cerebral palsy, consisting of a total of 88 items.

    Functional performance is assessed across five domains: (A) lying and rolling, (B) sitting, (C) crawling and kneeling, (D) standing, and (E) walking, running, and jumping. The score for each domain is calculated and expressed as a percentage.

    Measured: Outcomes will be assessed at week 0, week 2, and week 4 for both treatment group and control group.

Secondary outcomes (2)
  1. 10-Meter Walk Test (10MWT)

    The time required for the subject to walk 10 meters will be measured to calculate gait speed. This test provides a simple and reliable method for objectively assessing gait ability and functional mobility.

    Measured: Outcomes will be assessed at week 0, week 2, and week 4 for both treatment group and control group.

  2. Guardian Satisfaction Assessment

    Acceptability, usability, and perceived effectiveness of robot-assisted gait training will be assessed from the caregiver's perspective using a 7-point Likert scale. The minimum value is 1 and the maximum value is 7 . 1-point means "Not helpful at all", and 7-point means "Very helpful".

    The mean score across all items will be used as the total score. Individual item results will be reported separately, and internal consistency will be evaluated.

    Measured: Outcomes will be assessed at week 4 for both treatment group and control group.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Apr 2026
  2. Study start13 Apr 2026 (estimated)
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07539389
Sponsor's protocol ID
EXO-CIP-003
Status last verified
Apr 2026
First submitted
7 Apr 2026
Last updated
20 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Exoskeleton and Rehabilitation physical therapy in people with Cerebral Palsy (CP), run by COSMO ROBOTICS CO., Ltd at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 20 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Seung Hak Lee, Associate Professor (82 + 02) 3010-3795, seunghak@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gross Motor Function Measure 88 (GMFM-88) (time frame: Outcomes will be assessed at week 0, week 2, and week 4 for both treatment group and control group.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in